Faversani et al reported that high-throughput pharmacologic targeting of survivin family proteins with YM155 selectively potentiated the effect of doxorubicin, and induced tumor cell apoptosis in breast cancer cell types. The gene discussed is BIRC5; the disease is breast carcinoma.